Učitavanje...
Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
BACKGROUND: Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always...
Spremljeno u:
| Izdano u: | Leuk Res |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8190959/ https://ncbi.nlm.nih.gov/pubmed/28843161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2017.08.002 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|